CoChat

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Open access
Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H · 2014 · BMJ Open
Cited by 24

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Introduction: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI. Methods and analysis: 40 obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. Ethics and dissemination: The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes theoral and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Papers will be submitted to peer-reviewed journals. Trial registration: ClinicalTrials.gov identifier: NCT01794429 ; National Committee on Health Research Ethics project number: 36378; EudraCT nr: 2012-005404-17; The Danish Data Protection Agency project number: RHP-2012-027.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2013-004158

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Mukundan A Faulkner G Cohn T . Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;(8):CD006629. · DOI · Paper page
  2. 10.1007/s11892-010-0112-8 · DOI
  3. 10.1111/j.1467-789X.2009.00570.x · DOI · Paper page
  4. Megna, 2011, Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Ann Clin Psychiatry, 23, 131, 10.1177/104012371102300207 · DOI · Paper page
  5. 10.1161/CIRCULATIONAHA.109.192644 · DOI · Paper page
  6. 10.1016/j.maturitas.2009.11.026 · DOI
  7. Holst JJ . The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409–39. · DOI · Paper page
  8. 10.1176/appi.ajp.2013.12101344 · DOI
  9. Bomba, 2013, Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals, Cell Death, 4, e612, 10.1038/cddis.2013.139 · DOI · Paper page
  10. 10.2165/11635890-000000000-00000 · DOI · Paper page
  11. 10.1093/schbul/13.2.261 · DOI · Paper page
  12. Fastenau, 1996, Development and preliminary standardization of the ‘extended complex figure test’ (ECFT), J Clin Exp Neuropsychol, 18, 63, 10.1080/01688639608408263 · doi:10.1080/01688639608408263
  13. Bright P Jaldow E Kopelman MD . The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc 8:847–54. · DOI · Paper page
  14. Bjorner JB Thunedborg K Kristensen TS . The Danish SF-36 Health Survey : translation and preliminary validity studies 1998;51:991–9. · DOI · Paper page
  15. 10.1249/01.MSS.0000078924.61453.FB · DOI · Paper page
  16. 10.1186/1475-2891-12-75 · DOI · Paper page
  17. Colton, 2006, Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states, Prev Chronic Dis, 3, A42
  18. 10.1371/journal.pone.0055176 · DOI · Paper page
  19. Kolotkin, 2008, Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder, Obesity (Silver Spring), 16, 749, 10.1038/oby.2007.133 · DOI · Paper page
  20. Faulkner, 2010, Interventions to reduce weight gain in schizophrenia (review), Schizophr Bull, 33, 654, 10.1093/schbul/sbm022 · DOI · Paper page
  21. 10.1136/bmj.c869 · DOI · Paper page

Cited by

See all 24

Metadata

Authors
Ishøy, P. L., Knop, F. K., Broberg, B. V., Baandrup, L., Fagerlund, B., Jørgensen, N. R., Andersen, U. B., Rostrup, E., Glenthøj, B. Y., & Ebdrup, B. H.
Venue
BMJ Open
Publisher
BMJ
Published
2014-01
Volume
4
Issue
1
Pages
e004158
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2149821062
Cited by
24
References
14
FWCI
2.69
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.